Diaz AE, Mesa RA. Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia. Future Oncol 2018;14(9):797-807. Abstract
Gisslinger H et al. Final results from PROUD-PV a randomized controlled phase 3 trial comparing ropeginterferon alfa-2b to hydroxyurea in polycythemia vera patients. Proc ASH 2016;Abstract 475.
Gowin KL et al. Survival advantage to allogeneic transplant in patients with myelofibrosis with intermediate-1 or higher DIPSS score. Proc ASH 2018;Abstract 4288.
Gupta V et al. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. Haematologica 2016;101(12):e482-4. Abstract
Harrison CN et al. Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide. Br J Haematol 2018;182(2):279-84. Abstract
Harrison CN et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): A randomised, open-label, phase 3 trial. Lancet Haematol 2018;5(2):e73-81. Abstract
Harrison CN et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): A single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol 2017;4(7):e317-24. Abstract
Harrison CN et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood 2017;130(17):1889-97. Abstract
Mascarenhas J et al. Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: A sponsor-independent international study. Ann Hematol 2018;97(8):1369-74. Abstract
Mascarenhas J et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: A randomized clinical trial. JAMA Oncol 2018;4(5):652-9. Abstract
Mascarenhas J et al. Open label phase I study of single agent oral RG7388 (idasanutlin) in patients with polycythemia vera and essential thrombocythemia. Proc ASH 2017;Abstract 254.
Menghrajani K et al. Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis. Leuk Lymphoma 2018;[Epub ahead of print]. Abstract
Mesa RA et al. Impact on MPN symptoms and quality of life of front line pegylated interferon alpha-2a vs hydroxyurea in high risk polycythemia vera and essential thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 global phase III trial. Proc ASH 2018;Abstract 3032.
Mesa RA. Refining the management of polycythemia vera. Clin Adv Hematol Oncol 2018;16(9):587-9. Abstract
Mesa RA et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): An international, randomised, phase 3 trial. Lancet Haematol 2017;4(5):e225-36. Abstract
Mesa RA et al. SIMPLIFY-1: A phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naïve patients with myelofibrosis. J Clin Oncol 2017;35(34):3844-50. Abstract
Mughal TI et al. Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms. Hematol Oncol 2018;36(5):740-8. Abstract
Oh ST et al. Hepcidin suppression by momelotinib is associated with increased iron availability and erythropoiesis in transfusion-dependent myelofibrosis patients. Proc ASH 2018;Abstract 4282.
O’Sullivan JM, Harrison CN. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms. Mol Cell Endocrinol 2017;451:71-9. Abstract
Pardanani A et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial. JAMA Oncol 2015;1(5):643-51. Abstract
Scherber RM, Mesa RA. Managing myelofibrosis (MF) that “blasts” through: Advancements in the treatment of relapsed/refractory and blast-phase MF. Hematology Am Soc Hematol Educ Program 2018;2018(1):118-26. Abstract
Verstovsek S et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol 2017;10(1):156. Abstract
Verstovsek S et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol 2017;10(1):55. Abstract